The University of Zurich announces today an investigator initiated large-scale prospective randomized controlled clinical trial to assess the clinical impact of Cardiac Resynchronization Therapy (CRT) in heart failure patients.
In the first trial of its kind in the world, 60 patients who have recently suffered a major heart attack will be injected with selected stem cells from their own bone marrow during routine coronary bypass surgery.
Countless exercise programs claim to trim the thighs, abs and buttocks, but how many offer to reshape a flabby heart? According to new research, aerobic exercise does just that for patients with stable heart failure, literally turning an enlarged heart into a trimmer, more efficient organ for pumping blood throughout the body.
Epidemiologists at the University of Liverpool and the Heart of Mersey have found that approximately half the recent fall in coronary heart disease deaths in the US is due to positive life style changes and a further half to medical therapies.
FDA has requested a black box warning for the labels of the type 2 diabetes medications Avandia, manufactured by GlaxoSmithKline, and Actos, manufactured by Takeda Pharmaceuticals, because of increased risk for congestive heart failure associated with the medications, agency Commissioner Andrew von Eschenbach announced on Wednesday at a House Oversight and Government Reform Committee hearing, the New York Times reports.
Typified by high blood pressure, weight gain around the waist and problems regulating blood sugar, metabolic syndrome may also be associated with compromised heart structure and function, according to a paper published in the online open access journal BMC Cardiovascular Disorders.
Takeda Pharmaceuticals North America, Inc. (TPNA) announced that the company will revise warnings related to congestive heart failure (CHF) in the prescribing label of its type 2 diabetes medication ACTOS(R) (pioglitazone HCl).
On June 5, 2007, the New England Journal of Medicine published results of an interim analysis of the cardiovascular safety trial of rosiglitazone (brand name, Avandia).
GlaxoSmithKline [NYSE:GSK] said that findings from an interim analysis of RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes), a prospective clinical trial designed specifically to determine cardiovascular outcomes in more than 4,400 patients with type 2 diabetes, adds further evidence to the overall cardiovascular safety profile of Avandia? (rosiglitazone maleate).
Researchers at the University of Leeds (UK) have found a mechanism to prevent a potentially fatal heart condition that can strike without warning.